LURAP1L
Leucine rich adaptor protein 1-like
Also known as: bA3L8.2, C9orf150, FLJ38505, LRAP35b, LUR1L_HUMAN, MGC46502
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8IV03
- Gene
- LURAP1L
- Ensembl
- ENSG00000153714
- Chromosome
- 9
- Canonical length
- 228 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nucleoli
OverviewNCBI Gene
Predicted to be involved in positive regulation of canonical NF-kappaB signal transduction. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
228 residues, UniProt reviewed canonical sequence.
>Q8IV03|LURAP1L
1 MEDSPLPDLR DIELKLGRKV PESLVRSLRG EEPVPRERDR DPCGGSGGGG GGGGGCSSSS
61 SYCSFPPSLS SSSSSSPTSG SPRGSHSSAL ERLETKLHLL RQEMVNLRAT DVRLMRQLLV
121 INESIESIKW MIEEKATITS RGSSLSGSLC SLLESQSTSL RGSYNSLHDG SDGLDGISVG
181 SYLDTLADDV PGHQTPSDLD QFSDSSLIED SQALHKRPKL DSEYYCFGLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LURAP1L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.63
- Highest tissue expression
- 30 nTPM
Expression across tissuesHPA
Tissue
- liver: 30 nTPM
- placenta: 20 nTPM
- salivary gland: 19 nTPM
- blood vessel: 19 nTPM
- pancreas: 19 nTPM
- lung: 17 nTPM
Single-cell type
- epididymal efferent duct absorptive cells: 337 nCPM
- breast hormone-responsive cells: 303 nCPM
- pancreatic duct cells: 277 nCPM
- alveolar cells type 2: 200 nCPM
- salivary acinar cells: 173 nCPM
- colonocytes: 171 nCPM
Immune cell
- eosinophil: 0.1 nTPM
- total PBMC: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- cerebellum: 21 nTPM
- spinal cord: 8 nTPM
- white matter: 7.9 nTPM
- medulla oblongata: 7.1 nTPM
- pons: 6.5 nTPM
- thalamus: 6.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about LURAP1L.
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 64 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.38
- gnomAD pLI
- 0.03
- gnomAD missense Z
- -1.13
- DepMap mean gene effect
- 0.12
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LURAP1L as an antibody target. Whether an autoantibody or antibody against LURAP1L could matter depends on whether native LURAP1L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LURAP1L is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label LURAP1L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...